Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Chemical Research in Toxicology|February 4, 2011
Intrinsic electrophilicity of a 4-substituted-5-cyano-6-(2-methylpyridin-3-yloxy)pyrimidine derivative: structural characterization of glutathione conjugates in vitroAmit S Kalgutkar, Vincent Mascitti, Raman Sharma, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 9, 2007
Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activationAmit S Kalgutkar, Deepak K Dalvie, Jiri Aubrecht, et al.Bioorganic & Medicinal Chemistry Letters|February 12, 2011
Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptorVincent Mascitti, Benjamin D Stevens, Chulho Choi, et al.Plos Biology|April 18, 2018
Correction: Selective stalling of human translation through small-molecule engagement of the ribosome nascent chainNathanael G Lintner, Kim F McClure, Donna Petersen, et al.Plos Biology|March 22, 2017
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chainNathanael G Lintner, Kim F McClure, Donna Petersen, et al.Bioorganic & Medicinal Chemistry Letters|June 28, 2023
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groupsGary E Aspnes, Steven B Coffey, Etzer Darout, et al.Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Benzimidazolone p38 inhibitorsMark A Dombroski, Michael A Letavic, Kim F McClure, et al.ACS Medicinal Chemistry Letters|February 21, 2015
Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonistsSuvi T M Orr, Ramsay Beveridge, Samit K Bhattacharya, et al.Journal of Medicinal Chemistry|March 3, 2011
Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist responseKim F McClure, Etzer Darout, Cristiano R W Guimarães, et al.Journal of Medicinal Chemistry|June 8, 2018
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic AgentsAllyn T Londregan, Liuqing Wei, Jun Xiao, et al.Pageof 4